CA2368855A1 - Differentiation of monocytes into functional dendritic cells - Google Patents

Differentiation of monocytes into functional dendritic cells Download PDF

Info

Publication number
CA2368855A1
CA2368855A1 CA002368855A CA2368855A CA2368855A1 CA 2368855 A1 CA2368855 A1 CA 2368855A1 CA 002368855 A CA002368855 A CA 002368855A CA 2368855 A CA2368855 A CA 2368855A CA 2368855 A1 CA2368855 A1 CA 2368855A1
Authority
CA
Canada
Prior art keywords
monocytes
composition
disease
cells
incubated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002368855A
Other languages
French (fr)
Other versions
CA2368855C (en
Inventor
Richard Leslie Edelson
Carole L. Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368855A1 publication Critical patent/CA2368855A1/en
Application granted granted Critical
Publication of CA2368855C publication Critical patent/CA2368855C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Abstract

A method for inducing differentiation of monocytes contained in an extracorporeal quantity of a subject's blood into functional dendritic antigen presenting cells is provided. The monocytes are first treated by exposure to physical perturbation, irradiation in the presence of a photoactivatable agent capable of forming photoadducts with cellular DNA components, and/or treatment with a DNA binding agent. The treated monocytes are then incubated for a period of time sufficient to maximize the number of functional dendritic cells in the treated cell population. Functional dendritic cells generated from induced monocytes are incubated together with disease effector agents to enhance the presentation of at least one disease-causing antigen expressed by the disease effector agents. Compositions including dendritic cells derived from induced monocytes and compositions including such dendritic cells incubated with disease effector agents are also provided.

Claims (63)

1. A method for inducing differentiation of monocytes contained in an extracorporeal quantity of a subject's blood into functional dendritic antigen presenting cells, said method comprising the steps of:

(a) treating the monocytes by at least one of the following: (1) exposing the monocytes to physical perturbation, (2) irradiating the monocytes in the presence of a photoactivatable agent capable of forming photoadducts with cellular DNA components, and (3) treating the monocytes with a DNA binding agent; and (b) incubating the treated monocytes for a period of time sufficient to maximize the number of functional dendritic cells.
2. The method of claim 1, wherein prior to step (a) the method further comprises the step of:

separating the monocytes from the extracorporeal quantity of the subject's blood by subjecting the quantity of blood to a leukapheresis process.
3. The method of claim 2, wherein the monocytes are incubated for a period of from about 6 to about 48 hours.
4. The method of claim 3, wherein the monocytes are incubated for a period of from about 12 to about 24 hours.
5. The method of claim 3, wherein the monocytes are irradiated in the presence of the photoactivatable agent.
6. The method of claim 6, wherein the photoactivatable agent is 8-MOP.
7. The method of claim 3, wherein the monocytes are exposed to the DNA binding agent.
8. The method of claim 3, wherein the treated monocytes are incubated together with at least one of GM-CSF and IL-4.
9. The method of claim 3, wherein the monocytes are incubated in a container which does not leach substantial amounts of plasticizer and which is sufficiently porous to permit exchange of gases.
10. The method of claim 3, wherein the treated monocytes are incubated together with at least one selected antigen to be processed and presented by the dendritic cells.
11. The method of claim 10, wherein the at least one antigen is expressed on the surface of a disease effector agent.
12. The method of claim 11, wherein the disease effector agent is selected from the group consisting of disease-causing cells and microbes.
13. A composition comprising functional dendritic antigen presenting cells derived from monocytes which have been incubated following their treatment by at least one of: (1) exposure to physical perturbation, (2) irradiation in the presence of a photoactivatable agent capable of forming photoadducts with cellular components, and (3) treatment with a DNA binding agent.
14. The composition of claim 13, wherein the treated monocytes have been incubated for a period of time sufficient to maximize the number of functional dendritic cells present in the composition.
15. The composition of claim 14, wherein the treated monocytes have been incubated for a period of from about 6 to about 48 hours.
16. The composition of claim 15, wherein the monocytes have been incubated for a period of from about 12 to about 24 hours.
17. The composition of claim 14, wherein the monocytes have been irradiated in the presence of the photoactivatable agent.
18. The composition of claim 17, wherein the photoactivatable agent is 8-MOP.
19. The composition of claim 14, wherein the monocytes have been exposed to the DNA binding agent.
20. The composition of claim 14, further comprising at least one of GM-CSF and IL-4.
21. The composition of claim 14 further comprising at least one selected antigen for presentation by the dendritic cells.
22. The composition of claim 21, wherein the at least one antigen is expressed on the surface of a disease effector agent.
23. The method of claim 22, wherein the disease effector agent is selected from the group consisting of disease-causing cells and microbes.
24. A packaged preparation comprising:

a composition including functional dendritic antigen presenting cells derived from monocytes which have been incubated following their treatment by at least one of exposure to physical perturbation, irradiation in the presence of a photoactivatable agent capable of forming photoadducts with cellular components, and treatment with a DNA binding agent; and a container which does not leach substantial amounts of plasticizer and which is sufficiently porous to permit exchange of gases for storing the composition.
25. The packaged preparation of claim 24, wherein the treated monocytes have been incubated for a period of time sufficient to maximize the number of functional dendritic cells present in the composition.
26. The packaged preparation of claim 25, wherein the composition further includes at least one of GM-CSF and IL-4.
27. The packaged preparation of claim 25, wherein the composition further includes at least one selected antigen for presentation by the dendritic cells.
28. A method of enhancing the presentation of disease associated antigens, said method comprising the steps of:
(a) treating disease effector agents capable of expressing at least one disease associated antigen to one of: render the agents apoptotic and inactivate the agents;

(b) treating monocytes contained in an extracorporeal quantity of a subject's blood by at least one of the following: (1) exposing the monocytes to physical perturbation, (2) irradiating the monocytes in the presence of a photoactivatable agent capable of forming photoadducts with cellular components, and (3) treating the monocytes with a DNA binding agent; and (c) incubating the treated disease effector agents and the treated monocytes together for a period of time sufficient to induce differentiation of the monocytes into functional dendritic antigen presenting cells and to optimize processing and presentation of the disease associated antigens by the dendritic cells.
29. The method of claim 28, wherein the treated disease effector agents and the treated monocytes are incubated together for a period of from about 6 to about 40 hours.
30. The method of claim 29, wherein the treated disease effector agents and the monocytes are incubated together for a period of from about 12 to about 24 hours.
31. The method of claim 28, wherein the disease effector agents are contained in the extracorporeal quantity of the subject's blood.
32. The method of claim 28, wherein the disease effector agents are derived from an exogenous source.
33. The method of claim 31, wherein prior to step (a) the method further comprises the step of:

separating the disease effector agents and the monocytes from the extracorporeal quantity of the subject's blood by subjecting the quantity of blood to a leukapheresis process.
34. The method of claim 28, wherein the disease effector agents are selected from the group consisting of disease-causing cells and microbes.
35. The method of claim 34 wherein the disease-causing cells selected from the group consisting of T-cells, B-cells and macrophages.
36. The method of claim 35, wherein the T-cells include lymphoma cells.
37. The method of claim 36, wherein the lymphoma cells include cutaneous T-cell lymphoma cells.
38. The method of claim 28, wherein steps (a) and (b) are performed simultaneously by irradiating the disease effector agents and the monocytes with a photoactivatable agent capable of forming photoadducts with DNA and cell proteins.
39. The method of claim 38, wherein the photoactivatable agent is 8-MOP.
40. The method of claim 28, wherein the disease associated antigen is selected from the group consisting of viral antigens, fungal antigens, bacterial antigens, transplant antigens and tumor specific antigens.
41. The method of claim 40, wherein the tumor specific antigen is a peptide derived from a T-cell antigen-binding cell surface receptor.
42. The method of claim 28, wherein the disease effector agents and the monocytes are incubated together with at least one of GM-CSF, IL-4, TNF-alpha, and IL-12.
43. The method of claim 28, wherein the disease effector agents and the monocytes are incubated together in a container which does not leach substantial amounts of plasticizer.
44. The method of claim 28, further including the step of:
administering the incubated disease effector agents and the dendritic cells to the subject to elicit an immune response.
45. The method of claim 44, wherein the incubated disease effector agents and the dendritic cells are administered to the subject in at least one of the presence of and in combination with an immunomodulatory agent.
46. A composition of co-incubated populations comprising:
a first population including disease effector agents which express at least one disease associated antigen; and a second population including functional dendritic antigen presenting cells derived from monocytes which have been treated by at least one of (1) exposure to physical perturbation, (2) irradiation in the presence of a photoactivatable agent capable of forming photoadducts with cellular components, and (3) treatment with a DNA binding agent.
47. The composition of claim 46, wherein the first and second populations have been co-incubated for a period of from about 6 to about 40 hours.
48. The composition of claim 47, wherein the first and second populations have been co-incubated for a period of from about 12 to about 24 hours.
49. The composition of claim 46, wherein the disease effector agents are selected from the group consisting of disease-causing cells and microbes.
50. The composition of claim 49, wherein the disease-causing cells are selected from the group consisting of T-cell, B-cells and macrophages.
51. The composition of claim 50, wherein the T-cells include lymphoma cells.
52. The composition of claim 51, wherein the lymphoma cells include cutaneous T-cell lymphoma cells.
53. The composition of claim 46, wherein the disease effector agents and the monocytes have been treated with a photoactivatable agent.
54. The composition of claim 53, wherein the photoactivatable agent is 8-MOP.
55. The composition of claim 46, wherein the disease effector cells and the monocytes have been treated with a DNA binding agent.
56. The composition of claim 46, wherein the monocytes are separated from an extracorporeal quantity of a subject's blood.
57. The composition of claim 56, wherein the disease effector agents are one of contained in the extracorporeal quantity of the subject's blood and derived from an exogenous source.
58. The composition of claim 46, wherein the disease associated antigen is selected from the group consisting of viral antigens, fungal antigens, bacterial antigens, transplant antigens, and tumor specific antigens.
59. The composition of claim 46, further including at least one immunomodulatory agent.
60. A packaged composition of co-incubated populations comprising:
a first population including disease effector agents which express at least one disease associated antigen;
a second population including functional dendritic antigen presenting cells derived from monocytes which have been treated by at least one of: (1) exposure to physical perturbation, (2) irradiation in the presence of a photoactivatable agent capable of forming photoadducts with cellular components, and (3) treatment with a DNA binding agent; and a container which does not leach substantial amounts of plasticizer and which is sufficiently porous to permit exchange of gases for storing the composition.
61. A method of providing a vaccine against disease effector agents capable of expressing at least one disease associated antigen; said method comprising the steps of:

(a) treating the disease effector agents to one of: render the agents apoptotic and inactivate the agents;

(b) treating monocytes contained in an extracorporeal quantity of a subject's blood by at least one of the following: (1) exposing the monocytes to physical perturbation, (2) irradiating the monocytes in the presence of a photoactivatable agent capable of forming photoadducts with cellular components, and (3) treating the monocytes with a DNA binding agent;

(c) incubating the treated disease effector agents and the treated monocytes together for a period of time sufficient to induce differentiation of the monocytes into functional dendritic antigen presenting cells and to optimize processing and presentation of the disease associated antigens by the dendritic cells;
and (d) administering the incubated disease effector agents and the dendritic cells to the subject to vaccinate the subject against the disease effector agents.
62. The method of claim 61, wherein the disease effector agents are selected from the group consisting of disease-causing cells and microbes.
63. The method of claim 61, wherein the disease effector agents are one of: contained in the extracorporeal quantity of the subject's blood and derived from an exogenous source.
CA2368855A 1999-04-20 2000-04-03 Differentiation of monocytes into functional dendritic cells Expired - Lifetime CA2368855C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29449499A 1999-04-20 1999-04-20
US09/294,494 1999-04-20
PCT/US2000/008793 WO2000062818A1 (en) 1999-04-20 2000-04-03 Differentiation of monocytes into functional dendritic cells
US10/066,021 US20020114793A1 (en) 1999-04-20 2002-01-31 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells

Publications (2)

Publication Number Publication Date
CA2368855A1 true CA2368855A1 (en) 2000-10-26
CA2368855C CA2368855C (en) 2012-05-29

Family

ID=42357263

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2368855A Expired - Lifetime CA2368855C (en) 1999-04-20 2000-04-03 Differentiation of monocytes into functional dendritic cells
CA002474571A Abandoned CA2474571A1 (en) 1999-04-20 2003-01-31 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002474571A Abandoned CA2474571A1 (en) 1999-04-20 2003-01-31 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells

Country Status (6)

Country Link
US (3) US6524855B2 (en)
EP (2) EP1176986B1 (en)
JP (1) JP2005515781A (en)
AU (1) AU782391B2 (en)
CA (2) CA2368855C (en)
WO (2) WO2000062818A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782391B2 (en) * 1999-04-20 2005-07-21 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US20080241815A1 (en) * 1999-04-20 2008-10-02 Edelson Richard L Methods for Inducing the Differentiation of Blood Monocytes into Functional Dendritic Cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
US20050084966A1 (en) * 1999-04-20 2005-04-21 Edelson Richard L. Methods for inducing the differentiation of blood monocytes into functional dendritic cells
US20050158856A1 (en) * 1999-04-20 2005-07-21 Edelson Richard L. Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
US7109031B2 (en) * 1999-04-20 2006-09-19 Yale University Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
DE10109618A1 (en) * 2001-02-28 2002-09-12 Eppendorf Ag Modifying antigen-presenting cells, useful e.g. in antitumor vaccines, by transfer to them of antigen-containing membrane fragments from diseased cells
US20050202098A1 (en) * 2001-01-31 2005-09-15 Tolaren Disease therapy using dying or dead cells
US7727523B2 (en) 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells
DE60235097D1 (en) 2001-08-13 2010-03-04 Univ Yale METHOD FOR INDUCING A SELECTIVELY IMPRESSED IMMUNE RESPONSE
DE60230997D1 (en) * 2001-12-05 2009-03-12 Caridianbct Inc METHOD AND DEVICE FOR SEPARATING BLOOD COMPONENTS
WO2005027841A2 (en) * 2003-09-16 2005-03-31 University Of North Carolina At Chapel Hill Cells, compositions and methods for repressing b cell autoantibody secretion and for treating autoimmune disease
AU2004294243B2 (en) * 2003-12-05 2011-02-17 Hopital Maisonneuve-Rosemont Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer
RU2278704C2 (en) * 2004-01-12 2006-06-27 Алексей Борисович Башкиров Method for inducing of immune response of mammalian organism-2
KR20200072566A (en) 2005-04-08 2020-06-22 코이뮨, 인크. Dendritic cell compositions and methods
JP5032792B2 (en) 2006-05-22 2012-09-26 浜松ホトニクス株式会社 Cell sorter
US20080035585A1 (en) * 2006-08-10 2008-02-14 Gambro Bct, Inc. Method and Apparatus for Recirculating Elutriation Fluids
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
GB0811856D0 (en) * 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
WO2011046832A2 (en) 2009-10-12 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Granulysin in immunotherapy
AU2013353573B2 (en) 2012-12-06 2019-01-17 Enlivex Therapeutics R&D Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
GB201300049D0 (en) 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
GB201300052D0 (en) 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-suppressive dendritic cells
WO2015187677A1 (en) * 2014-06-02 2015-12-10 Li-Cor, Inc. Phthalocyanine probes and uses thereof
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
RU2590696C2 (en) * 2014-09-22 2016-07-10 ФАНО России Федеральное государственное бюджетное учреждение науки Институт фундаментальных проблем биологии Российской академии наук (ИФПБ РАН) Agent for differentiation of monocyte-like cells
WO2017152008A1 (en) 2016-03-04 2017-09-08 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
WO2019222290A1 (en) * 2018-05-14 2019-11-21 Torque Therapeutics Inc. Peptide display to antigen presenting cells using lipid vehicle
CN113976052B (en) * 2021-11-03 2022-06-10 健进制药有限公司 Multivesicular liposome preparation system and preparation method thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321919A (en) 1979-12-11 1982-03-30 Leukocyte Research, Inc. Method and system for externally treating human blood
US4398906A (en) 1979-12-11 1983-08-16 Frederic A. Bourke, Jr. Method for externally treating the blood
US4428744A (en) 1979-12-11 1984-01-31 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4464166A (en) 1981-06-12 1984-08-07 Frederic A. Bourke, Jr. Method for externally treating the blood
US4612007A (en) 1981-06-16 1986-09-16 Edelson Richard Leslie Method and system for externally treating the blood
US4684521A (en) 1982-12-08 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4613322A (en) 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
US4683889A (en) 1983-03-29 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4838852A (en) 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5167657A (en) 1988-11-14 1992-12-01 Baxter International Inc. Plastic composition with anti-hemolytic effect
US20030072751A1 (en) 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
WO1993003766A1 (en) 1991-08-13 1993-03-04 Repligen Corporation Multiple antigen peptides for use as hiv vaccines
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US5731160A (en) 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
WO1994002156A1 (en) 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US5820872A (en) 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US5462733A (en) 1993-02-04 1995-10-31 Yale University Immune system modulation using psoralens activated with visible light
CN1118572A (en) 1993-03-05 1996-03-13 萨依特尔有限公司 HLA-A2.1 combined peptide and application of same
EP0692973A1 (en) 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
DE4412794A1 (en) 1994-04-14 1995-12-14 Univ Ludwigs Albert Process for producing dendritic cells, cells thus obtained and containers for carrying out this process
IL109540A0 (en) 1994-05-03 1994-08-26 Yeda Res & Dev Synthetic peptides and their use in tumor diagnosis and therapy
US6010905A (en) 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
AU2331597A (en) 1996-03-22 1997-10-10 Yale University Methods for inducing immune responsiveness in a subject
US20020098469A1 (en) 1996-03-22 2002-07-25 Morgan ,Lewis, Bockius Llp Extracorporeal methods for enhancing antigen presentation and immune responsiveness
AU782391B2 (en) * 1999-04-20 2005-07-21 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells

Also Published As

Publication number Publication date
AU4190400A (en) 2000-11-02
US6607722B2 (en) 2003-08-19
AU782391B2 (en) 2005-07-21
CA2474571A1 (en) 2003-08-07
EP1478735A1 (en) 2004-11-24
EP1478735A4 (en) 2006-08-02
US6524855B2 (en) 2003-02-25
WO2003064632A1 (en) 2003-08-07
US20010053355A1 (en) 2001-12-20
WO2000062818A1 (en) 2000-10-26
EP1176986A4 (en) 2004-06-16
JP2005515781A (en) 2005-06-02
CA2368855C (en) 2012-05-29
EP1176986B1 (en) 2018-07-04
EP1176986A1 (en) 2002-02-06
US20020004044A1 (en) 2002-01-10
US20020114793A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
CA2368855A1 (en) Differentiation of monocytes into functional dendritic cells
JP2958372B2 (en) How to prepare T cells
JPH08503470A (en) Specific immune system modulation
US4861704A (en) Processes for development of acceptance of transplanted organs and tissues
JP2004526455A (en) A method for producing highly active human dendritic cells from monocytes
US9790260B2 (en) Vaccine for tumor immunotherapy
US20050070463A1 (en) Use of gram-negative bacterial membrane fraction for inducing the maturation of dendritic cells
Kedar et al. Studies on the Induction and Expression of T Cell-Mediated Immunity: IV. Non-Overlapping Populations of Alloimmune Cytotoxic Lymphocytes with Specificity for Tumor-Associated Antigens and Transplantation Antigens
Russo et al. Leishmania: naive human T cells sensitized with promastigote antigen and IL-12 develop into potent Th1 and CD8+ cytotoxic effectors
TW200404002A (en) Treatment method achieved by using the lymphocytes derived from HLA matching donor-originating activated lymphocytes, formula having the lymphocytes as a main constituent thereof; method and preparation kit for manufacturing the formula
JP2015509382A (en) Organization structure and use thereof
JP2003523308A (en) Methods and devices for modulating an immune response
JPH11509521A (en) Pluripotent vaccine against enveloped viruses
Arione et al. A new childhood T-cell lymphoma established in nude mice and in vitro
Converse et al. Effect of cyclosporine on the response of normal human lymphocytes to cytomegalovirus in vitro
Lambert et al. Characterization of the antigen-presenting cell and T cell requirements for induction of pulmonary eosinophilia in a murine model of asthma
RU2447899C2 (en) Composition for treating hepatitis c and method of treating hepatitis c
BIBERFELD Recruitment of monocyte derived dendritic cells ex vivo from SIV infected and non infected cynomolgus monkeys
Bosma et al. Migration of allosensitizing donor myeloid dendritic cells into recipients after liver transplantation
AU572190B2 (en) Enhancing the acceptance of transplanted organ/tissue by uv radiation
Steinman Dendritic cells: clinical aspects
Mannhalter et al. Human T cell proliferation in response to E. coli presented by autologous macrophages is antigen specific.
Vallera et al. Tumor sponge implantation: An in vivo method for studying syngeneic, primary antitumor lymphocyte responses
Forger III et al. Thymic hormone modulation of leukemogenic virus replication
EP1624758A4 (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200403